BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY)'s Genentech (RHHBY) Grabs Alzheimer's Drug Rights From AC Immune SA for $418 Million-Plus


6/18/2012 7:34:28 AM

Roche Holding AG (ROG) bought the rights to an experimental drug for Alzheimer’s disease from closely held AC Immune, its second deal with the Swiss company. Roche’s Genentech unit will pay an undisclosed amount for rights to AC Immune’s anti-Tau antibodies, plus more than 400 million Swiss francs ($421 million) if the drugs meet targets, Lausanne-based AC Immune said in a statement today. Roche will also pay royalties on sales of the treatments. The deal gives Roche treatments against the second of what are thought to be the two main causes of Alzheimer’s, after buying the rights to crenezumab, a drug fighting the brain plaques that characterize the disease, from AC Immune in 2006. The memory-depleting disease affects 36 million people globally, a number that may double in 20 years.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES